{"filing":{"accession_number":"0001628280-26-038220","cik":"0001357874","ticker":"DTIL","company_name":"PRECISION BIOSCIENCES INC","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"dtil-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026038220/dtil-20260521.htm"},"events":[{"id":9164,"run_id":8041,"accession_number":"0001628280-26-038220","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Precision BioSciences held its annual meeting of stockholders on May 21, 2026, with shareholders voting on six proposals including director elections (Melinda Brown and Geno Germano), auditor ratification (Deloitte \u0026 Touche LLP), executive compensation approval, and amendments to the 2019 Incentive Award Plan and Certificate of Incorporation. All proposals were approved by shareholders.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1673,"accession_number":"0001628280-26-038220","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Incentive Award Plan, which increased the share pool available for equity compensation by 3,800,000 shares. This is a compensatory arrangement amendment requiring shareholder approval, fitting the exec_compensation category. The event is material as it affects the potential dilution and equity compensation capacity available to executives and employees.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1674,"accession_number":"0001628280-26-038220","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns a stockholder-approved amendment to the Certificate of Incorporation to add officer exculpation provisions permitted under Delaware law. While the amendment was formally approved and filed, it is a routine corporate governance modification that does not affect the company's financial condition, operations, or investor risk profile. The exculpation provision is a standard protective measure for officers and does not constitute a material event that would alter a reasonable investor's assessment of the registrant's business or financial standing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1675,"accession_number":"0001628280-26-038220","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Precision BioSciences' May 21, 2026 annual meeting of stockholders, covering six proposals including director elections (Melinda Brown and Geno Germano), auditor ratification (Deloitte \u0026 Touche LLP), executive compensation approval, and amendments to the 2019 Incentive Award Plan and Certificate of Incorporation. The filing explicitly states the voting tallies and outcomes for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1673,"accession_number":"0001628280-26-038220","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Incentive Award Plan, which increased the share pool available for equity compensation by 3,800,000 shares. This is a compensatory arrangement amendment requiring shareholder approval, fitting the exec_compensation category. The event is material as it affects the potential dilution and equity compensation capacity available to executives and employees.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-26"},{"id":1674,"accession_number":"0001628280-26-038220","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns a stockholder-approved amendment to the Certificate of Incorporation to add officer exculpation provisions permitted under Delaware law. While the amendment was formally approved and filed, it is a routine corporate governance modification that does not affect the company's financial condition, operations, or investor risk profile. The exculpation provision is a standard protective measure for officers and does not constitute a material event that would alter a reasonable investor's assessment of the registrant's business or financial standing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-26"},{"id":1675,"accession_number":"0001628280-26-038220","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Precision BioSciences' May 21, 2026 annual meeting of stockholders, covering six proposals including director elections (Melinda Brown and Geno Germano), auditor ratification (Deloitte \u0026 Touche LLP), executive compensation approval, and amendments to the 2019 Incentive Award Plan and Certificate of Incorporation. The filing explicitly states the voting tallies and outcomes for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:36:20.512222+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-05-26"}]}